Challenges for clinical trials to treat progressive multifocal leukoencephalopathy

Journal of NeuroVirology

Volumn 9, Issue SUPPL. 1, 2003, Pages 68-72

  Clifford, David B ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; HIV; Human immunodeficiency virus; JC virus; PML; Progressive multifocal leukoencephalopathy

Indexed keywords

AGNOPROTEIN; ANTIRETROVIRUS AGENT; CHLORPROMAZINE; CIDOFOVIR; CYTARABINE; CYTOKINE; GENE PRODUCT; INTERFERON; INTERLEUKIN 2; PHENOTHIAZINE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOPTIVE TRANSFER; ARTICLE; BRAIN BIOPSY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; DISEASE COURSE; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; LETHALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SYMPTOMATOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS; JC VIRUS;

EID: 0038136753     PISSN: 13550284     EISSN: None     Source Type: Journal    
DOI: 10.1080/13550280390195324     Document Type: Article

References (19)

1. Antinori A, Ammassari A, Cinque P, Toma L, Govoni A, Soldani F, Giancola ML, Grisetti S, Pierotti C, Fausti C, Finazzi MG, Bini T, Del Grosso B, Cristiano L, Corsi P, Fasulo G, Mena M, Guaraldi G, Arcidiacono MI, Monno L, Gigli B, Fibbia GC, Gentile M, Mastroianni A, Speranza F, d'Arminio Monforte A, Rezza G, Ippolito G (2001). Shift of prevalence and selected characteristics in HIV-1-related neurologic disorders in HAART era: data from Italian Register Investigative Neuro AIDS (IRINA). Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, Feb 4-8.
2. Atwood WJ (2001). A combination of low-dose chlorpromazine and neutralizing antibodies inhibits the spread of JC virus (JCV) in a tissue culture model: implications for prophylactic and therapeutic treatment of progressive multifocal leukencephalopathy. J NeuroVirol 7: 307-310.
3. Berger JR, Levy RM, Flomenhoft D, Dobbs M (1998). Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol 44: 341-349.
4. Cinque P, Casari S, Bertelli D (1998). Progressive multifocal leukoencephalopathy, HIV and highly active antiretroviral therapy. N Engl J Med 339: 848-849.
5. Clifford DB, Neurological AIDS Research Consortium Study Team (1998). Impact on highly active antiretroviral therapy on survival from progressive multifocal leukoencephalopathy in human immunodeficiency virus infection. Neurology 50: A249.
6. Clifford DB, Yiannoutsos C, Glicksman M, Simpson DM, Singer EJ, Piliero PJ, Marra CM, Francis GS, McArthur JC, Tyler KL, Tselis AC, Hyslop NE (1999). HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 52: 623-625.
7. Dworkin MS, Wan PT, Hanson DL, Jones JL, Adult & Adolescent Spectrum of HIV Disease Project (1999). Progressive multifocal leukoencephalopathy: improved survival of human immunodeficiency virus-infected patients in the protease inhibitor era. J Infect Dis 180: 621-625.
8. Geschwind MD, Skolasky RI, Royal WS, McArthur JC (2001). The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS. J NeuroVirol 7: 353-357.
9. Giudici B, Vaz B, Bossolasco S, Casari S, Brambilla AM, Lüke W, Lazzarin A, Weber T, Cinque P (2000). Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response. Clin Infect Dis 30: 95-99.
10. Hall CD, Dafni U, Simpson D, Clifford DB, Wetherill PE, Cohen B, McArthur JC, Hollander H, Yiannoutsos C, Major E, Millar L, Timpone J, AIDS Clinical Trials Group 243 Team (1998). Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. N Engl J Med 338: 1345-1351.
11. Hou J, Major EO (1998). The efficacy of nucleoside analogs against JC virus multiplication in a persistently infected human fetal brain cell line. J NeuroVirol 4: 451-456.
12. Inui K, Miyagawa H, Sashihara J, Miyoshi H, Tanaka-Taya K, Nishigaki T, Teraoka S, Mano T, Ono J, Okada S (1999). Remission of progressive multifocal leukoencephalopathy following highly active antiretroviral therapy in a patient with HIV infection. Brain Dev 21: 416-419.
13. Langford TD, Letendre SL, Marcotte TD, Ellis RJ, McCutchan JA, Grant I, Mallory ME, Hansen LA, Archibald S, Jernigan T, Masliah E, HNRC Group (2002). Severe, demyelinating leukoencepahlopathy in AIDS patients on antiretroviral therapy. AIDS 16: 1019-1029.
14. Levy RM, Major E, Ali MJ, Cohen B, Groothius D (2001). Convection-enhanced intraparenchymal delivery (CEID) of cytosine arabinoside (AraC) for the treatment of HIV-related progressive multifocal leukoencephalopathy (PML). J NeuroVirol 7: 382-385.
15. Marra CM, Rajicic N, Barker DE, Cohen BA, Clifford D, Post MJD, Ruiz A, Bowen BC, Huang ML, Queen-Baker J, Andersen J, Kelly S, Shriver S, ACTG 363 Team (2002). A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS 16: 1-7.
16. Pho MT, Ashok A, Atwood WJ (2000). JC virus enters human glial cells by clathrin-dependent receptor-mediated endocytosis. J Virol 74: 2288-2292.
17. Razonable RR, Aksamit AJ, Wright AJ, Wilson JW (2001). Cidofovir treatment of progressive multifocal leukoencephalopathy in a patient receiving highly active antiretroviral therapy. Mayo Glin Proc 76: 1171-1175.
18. Tantisiriwat W, Tebas P, Clifford DB, Powderly WG, Fichtenbaum CJ (1999). Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy. Clin Infect Dis 28: 1152-1154.
19. Tassie JM, Gasnault J, Bentata M, Deloumeaux J, Boué F, Billaud E, Costagliola D, Clinical Epidemiology Group from the French Hospital Database on HIV (1999). Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. AIDS 13: 1881-1887.